In a phase 1 investigation, an anti-mesothelin-specific ADC called anetumab ravtansine was found to have promising antitumor efficacy and a tolerable safety record in mesothelioma patients who had already received treatment. The gene discussed is MSLN; the disease is mesothelioma.